Only 12% of patients with solid tumors are served by immunotherapy drugs available today.

We are inventing new hope for cancer patients by targeting untapped metabolic signaling pathways to restore anti-tumor immunity and provide better outcomes for patients.

We are inventing new hope for cancer patients by targeting untapped metabolic signaling pathways to restore anti-tumor immunity and provide better outcomes for patients.